** Telehealth firm Hims & Hers' shares gain 2% to $19.75 premarket
** Company says former deputy commissioner at U.S. Food and Drug Administration, Deb Autor, will join Hims & Hers' board
** Autor oversaw FDA's inspections and international operations between 2011 and 2013 and has also served as the agency's director of the Office of Compliance for the Center for Drug Evaluation and Research
** Company also appoints Janet Stevens as its global head of quality and safety, who most recently served as quality officer at Baxter's Hillrom unit
** HIMS offers compounded versions of semaglutide, the active ingredient in Novo Nordisk's popular weight-loss drug Wegovy
** As of last close, HIMS shares have more than doubled this year
(Reporting by Bhanvi Satija in Bengaluru) ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.